India, April 14 -- Travere Therapeutics, Inc. (TVTX) shares jumped 31.57 percent to $40.42, gaining $9.72 on Monday, after the company received U.S. Food and Drug Administration approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis.
The stock is currently trading at $40.42, up from its previous close of $30.70 on the Nasdaq. It opened at $41.53 and has traded in a range of $39.90 to $42.50 during the session, with volume reaching 6.94 million shares compared to an average of 1.52 million shares.
The approval marks FILSPARI as the first and only FDA-approved treatment for FSGS, expanding its use beyond IgA nephropathy. Clinical data showed significant reductions in proteinuria, supporting its potential as a key the...